Fact CheckerSign in

NCT04128332Completed

Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer

Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery in Pancreatic Adenocarcinoma: A Window of Opportunity Feasibility Study

Source: ClinicalTrials.gov · Last updated 20 Apr 2026

Brief summary (registry, in English)

A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.

Status (registry)
Completed
Study type
Interventional
Enrollment
10 (actual)
First submitted
8 Oct 2019
Start date
Oct 2020
Primary completion date
Jan 2025
Lead sponsor
CCTU- Cancer Theme
NCT number
NCT04128332

What you commit to

  • Study type: Interventional
  • Participants enrolled: 10
  • From Oct 2020 to the primary completion date, Jan 2025
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous abdominal radiotherapy

Other illness

  • Any condition or abnormalities that in the judgement of the investigator/surgeon/clinical oncologist would place the patient at undue risk

Other

  • Women who are known to be pregnant
  • Women of child-bearing potential who are unwilling to use 2 highly effective forms of contraception during the study treatment period

Who the study is looking for

  • Have given written informed consent to participate in stage 1
  • Be aged 16 years or over at the time of signing the informed consent form
  • Presence of a hypodense pancreatic mass on contrast enhanced CT scan highly suspicious of operable primary pancreatic cancer as assessed by a pancreatic multi-disciplinary team (MDT)
  • Have not had pre-operative systemic therapy or radiotherapy
  • Have participated in stage 1 of the study
  • Have confirmed histological or cytological diagnosis of primary pancreatic adenocarcinoma OR radiological evidence of pancreatic head mass with supportive cytological or histological findings.
  • Be scheduled to undergo pancreatico-duodenectomy (Whipple's) resection.
  • Written informed consent to participate in stage 2
  • Aged 16 years or over at the time of signing informed consent
  • Have not had pre-operative systemic therapy or radiotherapy
  • ECOG Performance status 0-1
  • Adequate renal function: GFR ≥ 60

Age in the registry: 16 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Addenbrookes Hospital
Coordinator of this site? Confirm its status
CambridgeUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.